Cart
sales@molnova.com
JND3229
CAS No. 2260886-64-2
JND3229( —— )
Catalog No. M33389 CAS No. 2260886-64-2
JND3229 is a reversible EGFRC797S inhibitor with IC50 values of 5.8, 6.8 and 30.5 nM for EGFRL858R/T790M/C797S, EGFRWT and EGFRL858R/T790M, respectively.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 2MG | 84 | Get Quote |
|
| 5MG | 123 | Get Quote |
|
| 10MG | 188 | Get Quote |
|
| 500MG | Get Quote | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameJND3229
-
NoteResearch use only, not for human use.
-
Brief DescriptionJND3229 is a reversible EGFRC797S inhibitor with IC50 values of 5.8, 6.8 and 30.5 nM for EGFRL858R/T790M/C797S, EGFRWT and EGFRL858R/T790M, respectively.
-
DescriptionJND3229 is a reversible EGFRC797S inhibitor with IC50 values of 5.8, 6.8 and 30.5 nM for EGFRL858R/T790M/C797S, EGFRWT and EGFRL858R/T790M, respectively. JND3229 has good anti-proliferative activity and can effectively inhibit tumour growth in vivo. JND3229 can be used in cancer research, especially in non-small cell carcinoma.
-
In VitroWestern Blot AnalysisCell Line:BaF3 cells (overexpressing EGFRL858R/T790M/C797S or EGFR19D/T790M/C797S) Concentration:0.1, 0.3, 1, 3, 10 μM Incubation Time:2 h Result:Significantly inhibited the phosphorylation of EGFRL858R/T790M/C797S and EGFR19D/T790M/C797S in a dose-dependent manner.
-
In VivoAnimal Model:BALB/c mice (bearing established BaF3-EGFR19D/T790M/C797S mouse xenograft tumors model).Dosage:10 mg/kg Administration:Intraperitoneal injection; twice daily for 10 days.Result:Caused an obvious suppression of tumor growth with a Tumor Growth Inhibition (TGI) value of 42.2%.Showed well tolerance without obvious body weight loss or other obvious toxic sign in the treated animals.Significantly decreased the level of phosphorylated EGFR (p-EGFR) tin the tumor tissues.
-
Synonyms——
-
PathwayAngiogenesis
-
TargetEGFR
-
RecptorEGFR
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number2260886-64-2
-
Formula Weight617.18
-
Molecular FormulaC33H41ClN8O2
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 12.5 mg/mL (20.25 mM; Ultrasonic )
-
SMILESCCC(=O)N[C@H]1CC[C@@H](CC1)N1C(=O)N(Cc2cnc(Nc3ccc(N4CCN(C)CC4)c(C)c3)nc12)c1ccccc1Cl
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Lu X, et al. Discovery of JND3229 as a New EGFRC797S Mutant Inhibitor with In Vivo Monodrug Efficacy. ACS Med Chem Lett. 2018 Oct 8;9(11):1123-1127.?
molnova catalog
related products
-
ARRY380
ARRY-380 is a potent and selective HER2 inhibitor with IC50 of 8 nM.
-
DBPR112
DBPR112 is an orally active furanopyrimidine-based EGFR inhibitor with IC50s of 15 nM for EGFRWT and 48 nM for EGFRL858R/T790M, capable of occupying the ATP-binding site and demonstrating significant antitumor efficacy.
-
HER2/neu (654-662) G...
Affibody (affibody) ligands that are specific for the extracellular domain of human epidermal growth factor receptor 2 (HER2/neu) have been selected by phage display technology from a combinatorial protein library based on the 58 amino acid residue staphylococcal protein A-derived Z domain.
